v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Information [Abstract]  
Segment Information

Note 10 – Segment Information

 

The Company conducts business as a single operating segment which is based upon the Company’s organizational and management structure, as well as information used by the Chief Operating Decision Maker (“CODM”) to allocate resources and other factors. The accounting policies of the segment are the same as those described in Note 2. The key measure of segment profitability that the CODM uses to allocate resources and assess performance is consolidated net income (loss), as reported on the unaudited condensed consolidated statements of operations. The following table presents the significant revenue and expense categories of the Company’s single operating segment.

 

   For the three months ended March 31, 
   2025   2024 
   (Unaudited)   (Unaudited) 
Operating expenses:        
Clinical trial related service fee   1,375,000    
-
 
Consulting fee   25,000    25,000 
Stock-based compensation   159,095    
-
 
Salary expense   129,711    120,486 
Professional fee   285,090    199,156 
Insurance expense   81,057    87,493 
Other general and administrative fee   49,345    37,395 
Loss before income tax   2,104,298    469,530 
           
Income tax expense   13    
-
 
Net loss  $2,104,311   $469,530